return equiti ttm
anoth solid quarter ge biopharma acquisit dental spin-off
track complet second half
result report revenu increas organ acquisit
foreign currenc billion ahead consensu estim billion
organ basi segment revenu increas life scienc diagnost
environment appli solut dental segment report
declin total organ revenu growth ahead guidanc adjust
ep increas year-over-year consensu estim
 manag said compani track complet acquisit ge
biopharma second half spin-off dental segment also
track take place second half year segment expect undergo
initi public offer new entiti known envista
guidanc manag introduc third quarter adjust ep guidanc rang
translat growth year-over-year consensu estim
prior releas manag forecast core revenu growth third
quarter approxim full year manag rais lower end
adjust ep guidanc rang previous consensu
estim releas increas low end rang
reflect strong first-half perform high end left unchang due
expect increment headwind second half year foreign-curr
translat tariff midpoint updat full-year guidanc repres growth
valuat conclus trade time adjust ep
estim updat estim account ge biopharma
acquisit track close second half year share trade time
adjust ep estim multipl peer group
higher-growth diversifi industri time believ continu deserv
modest valuat premium group given expect above-averag growth
rate high qualiti depend compani earn longer term
expect share appreci line annual earn growth estim
low- midteen rang includ accret futur acquisit
result maintain outperform rate
diversifi global scienc technolog compani design manufactur market divers
line industri healthcare-rel product four strateg platformslif scienc diagnost
dental environment appli solut recur revenu account sale product
produc sold world-wide north america sale western europ develop
region high-growth market
pleas refer import disclosur page analyst certif page
william blair affili seek busi compani cover research report
result investor awar firm may conflict interest could affect object
report report intend provid person invest advic opinion recommend
herein take account individu client circumst object need intend
recommend particular secur financi instrument strategi particular client recipi
report must make independ decis regard secur financi instrument mention
segment detail growth rate refer section core growth rate
life scienc second-quart sale revenu increas year-over-year includ high-single-digit
growth beckman life scienc midsingle-digit growth sciex high-single-digit growth pall double-digit
growth pall life scienc manag note continu record double-digit core revenu growth
segment adjust oper margin expand basi point driven improv execut
diagnost second-quart sale revenu increas year-over-year includ midsingle-digit growth
beckman diagnost high-single-digit growth radiomet midsingle-digit growth leica biosystem
cepheid core revenu increas year-over-year driven strength high-growth market
sustain momentum north america segment adjust oper margin contract basi point second
quarter primarili headwind unfavor chang foreign exchang rate tariff
dental second-quart sale revenu declin year-over-year low-single-digit growth
specialti busi off-set declin tradit consum equip segment adjust oper margin
contract basi point year-over-year due lower volum foreign-curr translat impact
on-going invest new product develop segment remain track undergo initi public offer
second half new entiti known envista
environment appli solut second-quart sale revenu increas year-over-year
includ low-single-digit growth product identif videojet water qualiti busi report
midsingle-digit growth manag note sequenti improv packag busi segment adjust
oper margin expand basi point
life revenu oper diagnosticsrevenu revenu oper revenu oper environment appli solutionsrevenu revenu oper compani dataiii dentalcompon platform sale growth william blair
margin gross margin contract basi point year-over-year adjust oper expens term dollar
increas year-over-year contract basi point percentag sale result factor
adjust oper margin contract basi point year-over-year oper margin expand basi
point year-over-year second quarter
balanc sheet cash flow second quarter gener free cash flow billion year-over-
year result free-cash-flow-to-adjusted-net-incom convers ratio end second quarter danah
debt-to-capit ratio compani investor day decemb note taken debt
level around time ebitda financ acquisit past given healthi cash flow gener abil
de-lev quickli number would unreason look forward announc agreement
acquir februari translat roughli billion capac opportun head
pend acquisit includ cash purchas price billion expect fund billion
proce equiti offer complet first quarter remaind cash hand new debt
februari announc agreement ge ge outperform acquir biopharma busi
ge life scienc cash purchas price approxim billion account anticip tax benefit net
purchas price deal billion repres multipl approxim time expect ebitda
ge biopharma view reason valuat ge biopharma provid instrument consum softwar
support research discoveri process develop manufactur workflow biopharmaceut ge
biopharma expect gener revenu billion estim equat approxim
total sale transact expect close fourth quarter estim acquisit
accret adjust ep approxim first full year follow deal close
follow exhibit highlight major acquisit recent year
datetargetplatformoverviewestim price million sale prior year million price/salesfeb technologywith headquart westlak ohio radiomet develop manufactur distribut technolog advanc critic care test system blood ga electrolyt metabolit compani offer complet solut complex process blood ga analysi use innov instrument sampl product inform technologyth acquisit gendex mark entri dental busi gendex divis dentspli inc headquart de plain illinoi gendex lead manufactur dental imag product includ intra-or panoram x-ray machin digit radiographi system intra-or camera film technologykaltenbach voight gmbh headquart biberach germani world-wide leader design manufactur sale dental equip includ handpiec treatment unit diagnost system laboratori ontario canada trojan inc lead water treatment technolog compani largest instal base ultraviolet water treatment system oper around rmselectron testwith headquart cleveland ohio cardin radiat manag servic provid solut maintain safe regulatory-compli facil medic imag therapi print plcproduct identificationlinx headquart st ive cambridgeshir uk major player global code mark industri suppli focus rang industri non-contact code mark equip base inkjet laser testwith primari oper unit kingdom austria produc sell comprehens array electr measur solut use commerci industri medic technologywith primari oper charlott north carolina newberg oregon pelton manufactur sell broad rang dental equip includ treatment unit light steril cabinetri dental microsystemsmed technologybas germani leica microsystem lead global design produc innov high- precis imag system use life scienc relat networkselectron testbas rockvil maryland visual network lead provid network test applic perform manag solut becom part fluke network busi technologywith headquart newport beach california sybron dental specialti manufactur high technolog dental dental implant infect prevent product dental restor orthodont endodont infect prevent systemsmed technologyvis system base australia manufactur market autom instrument biochem reagent detect cancer infecti diseas compani possess valuabl intellectu properti associ instrument glen allen virginia chemtreat manufactur water treatment product chemic industri water treatment applic testbas beaverton oregon tektronix lead supplier test measur monitor product enabl design manufactur manag next-gener global commun network comput advanc technolog focu commun comput semiconductor consum electron military/aerospac educ industri group plcmedic technologygenetix headquart new milton hampshir uk provid scientist clinician solut imag intellig imag analysi facilit develop pharmaceut biotherapeut mainstream research clinic sciex md inc medic technologycalifornia-bas ab sciex lead design manufactur mass spectromet instrument use identifi quantifi specif molecul specif sampl typic applic includ proteom research drug develop food environment safeti test diagnost test molecular devic suppli high-perform bioanalytical instrument system consum acceler improv research product effect life scienc research drug instrumentselectron testohio-bas keithley instrument design develop manufactur market complex electron instrument system gear special need engin electron manufactur academ institut research product develop high-perform product test process idwith headquart ghent belgium eskoartwork full-servic solut provid digit packag design product market eskoartwork suit softwar hardwar solut help custom reduc digit design cycl time ensur integr throughout packag materi suppli chain coulter inc life scienc diagnosticsbas brea california beckman coulter design manufactur market laboratori system includ instrument chemistri softwar suppli biomed laboratori need product use rang applic pioneer medic research drug discoveri diagnost system found hospit physician incorporatedproduct idx-rit global leader color scienc technolog compani includ design industri color leader panton llc develop manufactur market support innov color solut measur system softwar color standard inc life scienc diagnosticsbas chatsworth california iri inc lead global vitro diagnost compani focus product analyz particl live cell form structur morpholog varieti bodi biocaredentalheadquart switzerland nobel biocar manufactur dental implant cad/cam-bas prosthet restor aesthet dental medic productslif scienc diagnosticsheadquart cincinnati oh devicor global leader anatom patholog laboratori solut instrument special breast biopsi instrument consum microbiologylif scienc diagnosticsth microbiolog piec siemen healthcar busi establish leader microbi identif antibiot sensit test id/ast sciencespal lead provid filtrat separ purif solut remov contamin separ substanc varieti solid liquid lead innov global molecular diagnost compani develop manufactur market accur easi use molecular system sciencesphenomenex manufactur distributor high-valu consum separ scienc compani lead player proprietari chromatographi dna life sciencesidt provid high-valu consum genom applic molecular biolog qpcr next gener sequenc synthet biolog gene edit molecular biopharmalif sciencesg biopharma lead provid instrument consum softwar support research discoveri process develop manufactur workflow biopharmaceut drug compani report william blair estimateschronolog major acquisit william blair
forecast shown tabl estim rel unchang updat estim
incorpor acquisit expect close second half
op figur billion except per-shar itemssourc factset william blair forecastdanah forecastwb forecast william blair
incom wb tax net ni share ep cont ebitda saleslif appli oper appli segment oper margin adjust amort expens sourc compani data william blair estimatesdanah varianc tabl william blair
life appli actualconsensusnewpreviousconsensu revenu adjust adj ebitda adjust consensu figur immedi prior earn releasesourc compani report william blair estimatesdanah corpor flash analyticsfisc second quarter earningstot revenu adj oper marginsadj epsfre revenu segment fy summaryresultsfi guidancefre scienc diagnost dental environment appli solut william blair
danah corp rate outperformjuli model thousand except per-shar item fiscal year end statement net good ex restr oper intang expens tax net discontinu convert prefer stock avail amort intang after-tax non-recurring expens extraordinari dividend net epsaverag dilut share dilut ep continu intang incom dividend dilut tax tax sale net good ex restr oper net rate net good ex restr oper net dilut compani data william blair estim william blair
analysisseg saleslif environment appli total net segment sale growthlif appli segment total segment saleslif appli segment segment oper profitlif environment appli total segment total adjust oper report segment oper profit marginlif appli total segment oper profitlif appli segment oper increment oper marginlif appli increment oper increment oper marginlif appli increment oper compani data william blair estimatesdanah corpor nyse thousand except per share import disclosur
